HCP Live June 9, 2024
Tim Smith

The global, real-world TRACE study was designed to improve the understanding of tralokinumab’s safety, efficacy, and clinical utilization in daily practice for eczema.

A recent global, real-world study suggests that tralokinumab is being prescribed for atopic dermatitis (AD) patients as a first-line biologic option for treatment within the US, with a heavy burden of disease among patients and substantial impacts on quality of life being observed.1

This study, titled ‘Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States,’ was published in the British Journal of Dermatologists. It was led by investigators such as April W. Armstrong, MD, MPH, professor and chief of dermatology at University...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Big Data, Provider, Survey / Study, Technology, Trends
Related Articles:
Data Is Not The Fossil Fuel Of AI
Succeeding In The Data And AI Marketplace: 5 Lessons For Monetizing Data And AI
This is where the data to build AI comes from
Experts Pinpoint AI, Predictive Analytics as Key to Addressing Health Care Challenges
Before You Can Trust AI And Machine Learning, You Have To Trust Your Data

Share This Article